March 2016

Feature

Perspectives

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

03/08/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...

...

03/08/2016

Journal of Clinical Pathways

Research Reports

Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices

03/08/2016

Robert M Rifkin, MD, FACP

Esprit Ma, MPH

Robyn Harrell, MS

Lina Asmar, PhD

Yanyan Zhu, PhD, MPH

Liviu Niculescu, MD

Vijayveer Bonthapally, PhD

Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....

...

03/08/2016

Journal of Clinical Pathways

Column

Counterpoint

ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways

03/08/2016

Winston Wong, PharmD, Editor-in-Chief

The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...

The...

03/08/2016

Journal of Clinical Pathways

Viewpoint

Greater Alignment Among Oncology Clinical Pathways is Needed

03/08/2016

Edward Stepanski, PhD

A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...

A...

03/08/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway

03/08/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Donald Ohloma, MS

Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...

...

03/08/2016

Journal of Clinical Pathways

Insights

Interview

Immunotherapies and the Future of Cancer Care

03/08/2016

Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...

Five...

03/08/2016

Journal of Clinical Pathways

Interview

The ASCO Perspective on Oncology Clinical Pathways

03/08/2016

In the face of rising health care costs, oncology clinical pathways have been well documented as an effective tool for reducing inefficiency and improving quality in cancer care. A 2014 study reviewing 642 patients...

In the...

03/08/2016

Journal of Clinical Pathways

News

Conference Coverage

2016 American Society of Clinical Oncology Quality Care Symposium

03/08/2016

JCP Editors

A number of recent initiatives have required health care providers to think more proactively about the value of the care they deliver. This is especially true in the treatment of patients with cancer, where...

...

03/08/2016

Journal of Clinical Pathways

Department

Research in Review

Stereotactic Body Radiation More Cost-Effective for Treating Prostate Cancer Than Standard Therapy

03/08/2016

JCP Editors

Stereotactic body radiotherapy (SBRT) with a robotic system is currently more cost-effective than standard regimens as well as SBRT delivered with other systems for the treatment of prostate cancer, according to a...

...

03/08/2016

Journal of Clinical Pathways

Research in Review

Drug Combinations Cost-Effective for Reducing Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma

03/08/2016

JCP Editors

A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with...

...

03/08/2016

Journal of Clinical Pathways

Current Issue

April 2024

Volume 10

Issue 2

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

Biliary Tract Cancers (BTCs) Unveiled: Expert Perspectives on Unique Challenges and Management Considerations

11/20/2023

In this supplement, learn about the complexities of biliary tract cancer (BTC) with insights from a distinguished expert panel. The supplement examines the patient journey to diagnosis and treatment of BTCs, evaluates the impact of the...

In this supplement, learn about...

11/20/2023

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Twitter

Editorial Correspondence

March 2016

Feature

Column

Insights

News

Department

Current Issue

Special Reports

Subscribe

Twitter

April 2016 Volume 2

Specialties

Events

Year Round Education

HMP Global Products